Showing results (851-860 of 1,142) with videos related to

Sort By:
Pageof 115
Zeitschrift Fur Gastroenterologie|June 18, 2009
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infectionK Deterding, J Wiegand, N Grüner, et al.
Hepatology Communications|July 7, 2020
HBV-RNA Co-amplification May Influence HBV DNA Viral Load DeterminationBenjamin Maasoumy, Anna Maria Geretti, André Frontzek, et al.
Antiviral Therapy|February 2, 2012
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatmentIngmar Mederacke, Cihan Yurdaydin, George N Dalekos, et al.
Journal of Virological Methods|April 1, 2017
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patientsJürgen Kurt Rockstroh, Jordan J Feld, Stéphane Chevaliez, et al.
European Journal of Immunology|November 29, 2021
Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatmentYanqin Du, Tanvi Khera, Benedikt Strunz, et al.
Proteins|October 28, 2003
Rosetta predictions in CASP5: successes, failures, and prospects for complete automationPhilip Bradley, Dylan Chivian, Jens Meiler, et al.
Journal of Virology|March 29, 2013
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patientsJulia Dietz, Sven-Eric Schelhorn, Daniel Fitting, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
Scientific Reports|October 3, 2019
Soluble immune markers in the different phases of chronic hepatitis B virus infectionSteffen B Wiegand, Bastian Beggel, Anika Wranke, et al.
Antiviral Therapy|March 14, 2019
Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant dataVedran Pavlovic, Lei Yang, Henry Lik-Yuen Chan, et al.
Pageof 115